nasuspharma.com (NSRX): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Nasus Pharma Ltd (NSRX) brings together leading chemists within a flexible R&D environment, incentivizing scientists with unique patents. The business is currently transitioning to mass production, which reduces costs and increases margins. This chart on GURU.Markets shows the EV/EBITDA metric at 0.00. Nasus Pharma Ltd (NSRX) leads the development of biochemical nasal barriers that effectively block virus penetration into the body.

NSRX Nasus Pharma Ltd.: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 11/15/2026

Metric breakdowns and analytics for Nasus Pharma Ltd. (NSRX)

- current price and projected stock value:

Stock Price Nasus Pharma Ltd.|NSRX - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value Nasus Pharma Ltd.|NSRX - Value Adjusted for Debt and Cash

- book value of equity indicators:

Net Assets per Single Share Nasus Pharma|NSRX - Company Net Assets|Market Value to Book Value Ratio nasuspharma.com|NSRX - Total Business Assets

- debt and solvency information:

- business earnings and investment ratios data:

NSRX - Final Profit|Expected Profit Nasus Pharma Ltd|NSRX - Market Cap to Net Income|Forward P/E Multiple Nasus Pharma Ltd|NSRX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Nasus Pharma|NSRX - Operating profit EBITDA|Earnings per share for the last twelve months Nasus Pharma|NSRX - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months nasuspharma.com|NSRX - Net earnings per share growth this year|Earnings growth forecast for next year Nasus Pharma Ltd

- sales and revenue data:

NSRX - Revenue and Sales Volume|Company Future Sales Volume Nasus Pharma Ltd|NSRX - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Nasus Pharma Ltd

Comprehensive company analysis:Nasus Pharma Ltd (NSRX)

This indicator compares the total enterprise value to operating profit before interest and taxes, allowing for an assessment of the real value of assets regardless of the debt load. By analyzing the EV/EBITDA multiple over time, an investor can filter out financial noise and identify risks of margin compression for Nasus Pharma (NSRX), whose profitability is currently constrained by the rigid terms of B2B contracts with distributors.

Competitors of Nasus Pharma Ltd

EV/EBITDA Multiple INDV (Indivior Corp)|EV/EBITDA Multiple collegiumpharma.com COLL|CRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Canopy Growth Corporation (CGC) - Enterprise Value to EBITDA Ratio|Canna Cabana (HITI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Aurora Cannabis (ACB) - EV/EBITDA Multiple|ACHV (Achieve Life Sciences Inc) - EV/EBITDA Multiple|Skye Bioscience Inc. (SKYE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Anebulo (ANEB)|Canndoc - Enterprise Value to Operating Income Before Depreciation|Nutriband - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation IGC|MIRA Pharmaceuticals - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FLGC (Flora Growth Corp.)|IMCC: EV/EBITDA Multiple|ADIL (Adial Pharmaceuticals) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artelo Biosciences Inc.|Enterprise Value to EBITDA Ratio Ensysce Biosciences (ENSC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization titanpharm.com (TTNP)|EV/EBITDA Multiple gnln.com (GNLN)|EV/EBITDA Multiple INM (inmedpharma.com)|EV/EBITDA Multiple Akanda Corp. AKAN|Enveric - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation BGXX (brightgreen.us)|HPCO: EV/EBITDA Multiple